TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1][3] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[4]
Clinical data | |
---|---|
Other names | FKB01MD |
Routes of administration | By mouth |
Pharmacokinetic data | |
Bioavailability | 17%[1] |
Elimination half-life | 4 hours[1] |
Chemical and physical data | |
3D model (JSmol) |
|
| |
|